Abbott's price target has been increased by UBS to $146, with a Buy rating on the shares. The firm attributes Abbott's modest sales and earnings per share (EPS) beats as a key factor in boosting confidence in the company's potential for double-digit growth in its MedTech segment in the future, along with high single-digit growth in total sales.
UBS analysts believe that the market is currently undervaluing the sustainability of Abbott's MedTech business growth trajectory. They view Abbott as a top-tier opportunity for investors seeking consistent sales growth in the high single-digit to low double-digit range.